Your browser doesn't support javascript.
CANreduce-SP-adding psychological support to web-based adherence-focused guided self-help for cannabis users: study protocol for a three-arm randomized control trial.
Mestre-Pintó, J I; Fonseca, F; Schaub, M P; Baumgartner, C; Alias-Ferri, M; Torrens, M.
  • Mestre-Pintó JI; Addiction Research Group (GRAd), Neuroscience Research Program, Hospital del Mar Medical Research Institute (IMIM), 08003, Barcelona, Spain. jmestre@imim.es.
  • Fonseca F; Department of Experimental and Health Sciences (CEXS), Universitat Pompeu Fabra, 08002, Barcelona, Spain. jmestre@imim.es.
  • Schaub MP; Addiction Research Group (GRAd), Neuroscience Research Program, Hospital del Mar Medical Research Institute (IMIM), 08003, Barcelona, Spain.
  • Baumgartner C; Department of Experimental and Health Sciences (CEXS), Universitat Pompeu Fabra, 08002, Barcelona, Spain.
  • Alias-Ferri M; Department of Psychiatry and Department of Pharmacology, School of Medicine, Universitat Autònoma de Barcelona (UAB), 08290, Cerdanyola del Vallès, Spain.
  • Torrens M; Swiss Research Institute for Public Health and Addiction, University of Zurich, Zurich, Switzerland.
Trials ; 23(1): 524, 2022 Jun 22.
Artigo em Inglês | MEDLINE | ID: covidwho-2317210
ABSTRACT

BACKGROUND:

Cannabis is the most-frequently used illicit drug in Europe. Over the last few years in Spain, treatment demand has increased, yet most cannabis users do not seek treatment despite the related problems. A web-based self-help tool, like CANreduce 2.0, could help these users to control their consumption.

METHODS:

This study protocol describes a three-arm randomized controlled trial (RCT) comparing the effectiveness of three approaches, in terms of reducing cannabis use among problematic cannabis users, the first two treatment arms including the Spanish version of CANreduce 2.0 (an adherence-focused, guidance-enhanced, web-based self-help tool) (1) with and (2) without psychological support; and the third group (3) treatment as usual (TAU). Study hypotheses will be tested concerning the primary

outcome:

change in the number of days of cannabis use over the previous week, comparing assessments at 6 weeks and 3 and 6 months follow-up between groups and against baseline. Secondary outcomes related to cannabis use will be tested similarly. Mental disorders will be explored as predictors of adherence and outcomes. Analyses will be performed on an intention-to-treat basis, then verified by complete case analyses.

DISCUSSION:

This study will test how effective the Spanish version of CANreduce 2.0 (CANreduce-SP) is at reducing both the frequency and quantity of cannabis use in problematic users and whether adding psychological support increases its effectiveness. TRIAL REGISTRATION This trial is registered with the Clinical Trials Protocol Registration and Results System (PRS) number NCT04517474 . Registered 18 August 2020, (Archived by archive.is https//archive.is/N1Y64 ). The project commenced in November 2020 and recruitment is anticipated to end by November 2022.
Assuntos
Palavras-chave

Texto completo: Disponível Coleções: Bases de dados internacionais Base de dados: MEDLINE Assunto principal: Cannabis / Aceitação pelo Paciente de Cuidados de Saúde / Abuso de Maconha / Aconselhamento Tipo de estudo: Estudo de coorte / Estudo experimental / Estudo observacional / Estudo prognóstico / Ensaios controlados aleatorizados Limite: Humanos Idioma: Inglês Revista: Trials Assunto da revista: Medicina / Terapêutica Ano de publicação: 2022 Tipo de documento: Artigo País de afiliação: S13063-022-06399-2

Similares

MEDLINE

...
LILACS

LIS


Texto completo: Disponível Coleções: Bases de dados internacionais Base de dados: MEDLINE Assunto principal: Cannabis / Aceitação pelo Paciente de Cuidados de Saúde / Abuso de Maconha / Aconselhamento Tipo de estudo: Estudo de coorte / Estudo experimental / Estudo observacional / Estudo prognóstico / Ensaios controlados aleatorizados Limite: Humanos Idioma: Inglês Revista: Trials Assunto da revista: Medicina / Terapêutica Ano de publicação: 2022 Tipo de documento: Artigo País de afiliação: S13063-022-06399-2